Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes

Bone Marrow Transplantation

Volumn 49, Issue 2, 2014, Pages 241-247

  Xiao, H W ^a,b   Luo, Y ^a   Lai, X Y ^a   Shi, J M ^a   Tan, Y M ^a   He, J S ^a   Xie, W Z ^a   Zheng, W Y ^a   Ye, X J ^a   Yu, X H ^a   Cai, Z ^a   Lin, M F ^a   Huang, H ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Guangzhou Liuhuaqiao Hospital   (China)

Author keywords

CMV; GVHD; Hematopoietic SCT; Polymorphism; TLR9

Indexed keywords

FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE DONORS; TOLL-LIKE RECEPTOR 4; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84893783588     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.160     Document Type: Article

References (46)

1. Taylor PA, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 2008; 112: 3508-3516.
2. Penack O, Holler E, van den Brink MR. Graft-vs-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 2010; 115: 1865-1872.
3. Brennan TV, Lin L, Huang X, Cardona DM, Li Z, Dredge K et al. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood 2012; 120: 2899-2908.
4. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
5. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192.
6. Hugot JP, Zaccaria I, Cavanaugh J, Yang H, Vermeire S, Lappalainen M et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol 2007; 102: 1259-1267.
7. Lorenz E, Schwartz DA, Martin PJ, Gooley T, Lin MT, Chien JW et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 384-387.
8. Elmaagacli AH, Koldehoff M, Hindahl H, Steckel NK, Trenschel R, Peceny R et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-vs-host disease in patients who underwent an allogeneic transplantation. Transplantation 2006; 81: 247-254.
9. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359: 1766-1777.
10. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graftvs-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089-1093.
11. Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA et al. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant 2009; 23: 33-38.
12. Pinana JL, Valcarcel D, Fernandez-Aviles F, Martino R, Rovira M, Barba P et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010; 45: 1449-1456.
13. Huang H, Lin M, Meng H, Qian W, Jin J, Huang J et al. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation]. Zhonghua Xue Ye Xue Za Zhi 2001; 22: 76-78.
14. Huang H, Zheng W, Lin M, Fu J, Zhang R. [Prophylaxis of acute graft-vs-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model]. Zhonghua Xue Ye Xue Za Zhi 2002; 23: 191-193.
15. Xiao H, Cao W, Lai X, Luo Y, Shi J, Tan Y et al. Immunosuppressive cytokine gene polymorphisms and outcome after related and unrelated hematopoietic cell transplantation in a chinese population. Biol Blood Marrow Transplant 2011; 17: 542-549.
16. Xiao HW, Lai XY, Luo Y, Shi JM, Tan YM, He JS et al. Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population. Bone Marrow Transplant 2011; 46: 400-407.
17. Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y et al. Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Haematologica 2012; 97: 1804-1812.
18. Holler E, Rogler G, Brenmoehl J, Hahn J, Herfarth H, Greinix H et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006; 107: 4189-4193.
19. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol 2007; 25: 4262-4269.
20. Nguyen Y, Al-Lehibi A, Gorbe E, Li E, Haagenson M, Wang T et al. Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel diseaseassociated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation. Blood 2010; 115: 3625-3631.
21. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
22. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
23. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387.
24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
25. Lazarus R, Klimecki WT, Raby BA, Vercelli D, Palmer LJ, Kwiatkowski DJ et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics 2003; 81: 85-91.
26. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6: 88-95.
27. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-167.
28. Calcaterra C, Sfondrini L, Rossini A, Sommariva M, Rumio C, Menard S et al. Critical role of TLR9 in acute graft-vs-host disease. J Immunol 2008; 181: 6132-6139.
29. Porrett PM, Yuan X, LaRosa DF, Walsh PT, Yang J, Gao W et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 2008; 181: 1692-1699.
30. Heimesaat MM, Nogai A, Bereswill S, Plickert R, Fischer A, Loddenkemper C et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-vs-host disease. Gut 2010; 59: 1079-1087.
31. Vaidya SA, Cheng G. Toll-like receptors and innate antiviral responses. Curr Opin Immunol 2003; 15: 402-407.
32. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004; 103: 1433-1437.
33. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513-520.
34. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004; 101: 3516-3521.
35. Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, Hart J et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007; 62: 766-772.
36. Tao K, Fujii M, Tsukumo S, Maekawa Y, Kishihara K, Kimoto Y et al. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis 2007; 66: 905-909.
37. Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, Rodrigues SD et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007; 21: 441-446.
38. Elmaagacli AH, Koldehoff M, Beelen DW. Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9. Bone Marrow Transplant 2009; 44: 295-302.
39. Elmaagacli AH, Steckel N, Ditschkowski M, Hegerfeldt Y, Ottinger H, Trenschel R et al. Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors. Bone Marrow Transplant 2011; 46: 702-708.
40. Bafica A, Scanga CA, Schito M, Chaussabel D, Sher A. Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors. J Immunol 2004; 172: 7229-7234.
41. Schlaepfer E, Audige A, von Beust B, Manolova V, Weber M, Joller H et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol 2004; 78: 12344-12354.
42. Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute vs latent HIV infection. J Immunol 2006; 176: 2888-2895.
43. Medzhitov R, Janeway Jr. C. The Toll receptor family and microbial recognition. Trends Microbiol 2000; 8: 452-456.
44. Chiffoleau E, Heslan JM, Heslan M, Louvet C, Condamine T, Cuturi MC. TLR9 ligand enhances proliferation of rat CD4\+ T cell and modulates suppressive activity mediated by CD4\+ CD25\+ T cell. Int Immunol 2007; 19: 193-201.
45. Li JL, Song WR, Czerwinski DK, Varghese B, Uematsu S, Akira S et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007; 179: 2493-2500.
46. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009; 113: 3546-3552.